Hacettepe University, Faculty of Health Sciences, Ankara, Turkey.
Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany.
Aliment Pharmacol Ther. 2017 May;45(10):1303-1318. doi: 10.1111/apt.14043. Epub 2017 Mar 21.
Iron deficiency anaemia (IDA) is a common complication of inflammatory bowel disease (IBD) associated with reduced quality of life and increased hospitalisation rates. While the best way of treating IDA in IBD patients is not clearly established, current European guidelines recommend intravenous iron therapy in IBD patients with severe anaemia or intolerance to oral iron compounds.
To compare the efficacy and tolerability of different intravenous iron formulations used to treat IDA in IBD patients in a systematic review and Bayesian network meta-analysis (NMA), PROSPERO registration number: 42016046565.
In June 2016, we systematically searched for studies analysing efficacy and safety of intravenous iron for IDA therapy in IBD. Primary outcome was therapy response, defined as Hb normalisation or increase ≥2 g/dL.
Five randomised, controlled trials (n = 1143 patients) were included in a network meta-analysis. Only ferric carboxymaltose was significantly more effective than oral iron [OR=1.9, 95% CrI: (1.1;3.2)]. Rank probabilities showed ferric carboxymaltose to be most effective, followed by iron sucrose, iron isomaltose and oral iron. Pooled data from the systematic review (n = 1746 patients) revealed adverse event rates of 12.0%, 15.3%, 12.0%, 17.0% for ferric carboxymaltose, iron sucrose, iron dextran and iron isomaltose respectively. One drug-related serious adverse event (SAE) each was reported for ferric carboxymaltose and iron isomaltoside, and one possibly drug-related SAE for iron sucrose.
Ferric carboxymaltose was the most effective intravenous iron formulation, followed by iron sucrose. In addition, ferric carboxymaltose tended to be better tolerated. Thus, nanocolloidal IV iron products exhibit differing therapeutic and safety characteristics and are not interchangeable.
缺铁性贫血(IDA)是炎症性肠病(IBD)的常见并发症,会降低生活质量并增加住院率。虽然目前尚未明确治疗 IBD 患者 IDA 的最佳方法,但欧洲指南推荐对严重贫血或不能耐受口服铁剂的 IBD 患者使用静脉铁治疗。
通过系统评价和贝叶斯网络荟萃分析(NMA)比较不同静脉铁制剂治疗 IBD 患者 IDA 的疗效和耐受性,PROSPERO 注册号:42016046565。
2016 年 6 月,我们系统地检索了分析静脉铁治疗 IBD 患者 IDA 疗效和安全性的研究。主要结局是治疗反应,定义为 Hb 正常化或增加≥2 g/dL。
纳入了 5 项随机对照试验(n=1143 例患者)的网络荟萃分析。只有羧基麦芽糖铁的疗效明显优于口服铁剂[OR=1.9,95%可信区间:(1.1;3.2)]。等级概率显示羧基麦芽糖铁最有效,其次是蔗糖铁、异麦芽糖铁和口服铁剂。系统评价的汇总数据(n=1746 例患者)显示羧基麦芽糖铁、蔗糖铁、葡聚糖铁和异麦芽糖铁的不良事件发生率分别为 12.0%、15.3%、12.0%和 17.0%。报道了各有 1 例与药物相关的严重不良事件(SAE),分别发生在羧基麦芽糖铁和异麦芽糖铁组,蔗糖铁组报道了 1 例可能与药物相关的 SAE。
羧基麦芽糖铁是最有效的静脉铁制剂,其次是蔗糖铁。此外,羧基麦芽糖铁的耐受性更好。因此,纳米胶体 IV 铁产品表现出不同的治疗和安全性特征,不能相互替代。